A decade ago, Andrew Lo desperately sought out a therapy for his mother’s lung cancer that had developed resistance to existing drugs.
As part of the quest, he met with two biotech executives. Lo, a finance professor at Massachusetts Institute of Technology, casually asked over lunch if funding influenced which drug programs the company prioritized. The company’s chief scientific officer shook his head, looking at the other executive and then Lo.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.